- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Urothelial carcinoma
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1680KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 276KB)
Avelumab – March 2021
Avelumab (urothelial carcinoma): Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®
Last updated
2 July 2021